INSM Insmed Inc

$198.76

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Insmed's upcoming earnings report, set for October 23, 2025, arrives at a pivotal moment as the company continues to navigate the competitive landscape of biopharmaceuticals with a market cap of approximately $34.3 billion. Analysts are projecting an EPS of $0.00, aligning with the whisper number, which suggests that expectations are tempered for this quarter. Revenue is anticipated to reach $114.87 million, a figure that will be closely scrutinized for signs of growth or stability in the company's product pipeline. Despite the absence of recent news, investors will be keen to see how Insmed's strategic initiatives and potential advancements in its therapeutic offerings might influence future earnings. This earnings release will serve as a crucial indicator of Insmed's ability to maintain momentum in a challenging market environment.

Updated On 11/21/2025

About Insmed Inc

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Website: https://www.insmed.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1104506
Address
700 US HIGHWAY 202/206, BRIDGEWATER, NJ, US
Valuation
Market Cap
$13.20B
P/E Ratio
nan
PEG Ratio
0.00
Price to Book
46.29
Performance
EPS
$-5.57
Dividend Yield
—
Profit Margin
-251.20%
ROE
-891.00%
Technicals
50D MA
$76.03
200D MA
$73.81
52W High
$84.91
52W Low
$21.92
Fundamentals
Shares Outstanding
182M
Target Price
$97.24
Beta
1.07

INSM EPS Estimates vs Actual

● Estimated
● Actual

INSM News & Sentiment

Nov 19, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Insmed Stock Rise on EU Nod for Lung Disease Drug, Brinsupri
INSM climbs after the EU clears Brinsupri as the first approved treatment for NCFB, backed by phase III ASPEN and phase II WILLOW results.
Nov 19, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Is State Street SPDR S&P Biotech ETF ( XBI ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Nov 18, 2025 • Benzinga SOMEWHAT-BULLISH
Peering Into Insmed Inc's Recent Short Interest - Insmed ( NASDAQ:INSM )
Insmed Inc's ( NYSE:INSM ) short interest as a percent of float has fallen 16.1% since its last report. According to exchange reported data, there are now 8.03 million shares sold short, which is 4.17% of all regular shares that are available for trading.
Nov 14, 2025 • Benzinga SOMEWHAT-BULLISH
If You Invested $1000 In Insmed Stock 10 Years Ago, You Would Have This Much Today - Insmed ( NASDAQ:INSM )
Insmed ( NASDAQ:INSM ) has outperformed the market over the past 10 years by 15.85% on an annualized basis producing an average annual return of 28.26%. Currently, Insmed has a market capitalization of $40.29 billion.
Nov 14, 2025 • Zacks Commentary NEUTRAL
Should Vanguard Small-Cap ETF ( VB ) Be on Your Investing Radar?
Style Box ETF report for VB ...
Oct 31, 2025 • Benzinga SOMEWHAT-BULLISH
Here's How Much $1000 Invested In Insmed 10 Years Ago Would Be Worth Today - Insmed ( NASDAQ:INSM )
Insmed ( NASDAQ:INSM ) has outperformed the market over the past 10 years by 12.7% on an annualized basis producing an average annual return of 25.23%. Currently, Insmed has a market capitalization of $41.43 billion.
Sentiment Snapshot

Average Sentiment Score:

0.256
50 articles with scored sentiment

Overall Sentiment:

Bullish

INSM Reported Earnings

Aug 07, 2025
Jun 30, 2025 (Pre market)
-0.4 Surprise
  • Reported EPS: $-1.70
  • Estimate: $-1.30
  • Whisper: —
  • Surprise %: -30.8%
May 08, 2025
Mar 31, 2025 (Pre market)
-0.22 Surprise
  • Reported EPS: $-1.42
  • Estimate: $-1.20
  • Whisper: —
  • Surprise %: -18.3%
Feb 20, 2025
Dec 31, 2024 (Pre market)
-0.09 Surprise
  • Reported EPS: $-1.32
  • Estimate: $-1.23
  • Whisper: —
  • Surprise %: -7.3%
Oct 31, 2024
Sep 30, 2024 (Pre market)
-0.05 Surprise
  • Reported EPS: $-1.27
  • Estimate: $-1.22
  • Whisper: —
  • Surprise %: -4.1%
Aug 08, 2024
Jun 30, 2024 (Pre market)
-0.67 Surprise
  • Reported EPS: $-1.94
  • Estimate: $-1.27
  • Whisper: —
  • Surprise %: -52.8%
May 09, 2024
Mar 31, 2024 (Pre market)
0.17 Surprise
  • Reported EPS: $-1.06
  • Estimate: $-1.23
  • Whisper: —
  • Surprise %: 13.8%
Feb 22, 2024
Dec 31, 2023 (Pre market)
-0.13 Surprise
  • Reported EPS: $-1.28
  • Estimate: $-1.15
  • Whisper: —
  • Surprise %: -11.3%
Oct 26, 2023
Sep 30, 2023 (Pre market)
0.02 Surprise
  • Reported EPS: $-1.11
  • Estimate: $-1.13
  • Whisper: —
  • Surprise %: 1.8%
Aug 03, 2023
Jun 30, 2023 (Pre market)
-0.65 Surprise
  • Reported EPS: $-1.78
  • Estimate: $-1.13
  • Whisper: —
  • Surprise %: -57.5%

Financials